Biopharma Largely Avoids Partisan Bloodbath At US Pricing Hearing
Democrats spent most of their time complaining about Senate Republicans' closed-door process for developing healthcare legislation, leaving little time for the expert witnesses to weigh in on drug pricing.
You may also be interested in...
US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.
Senators and witnesses rehashed years-old arguments and found little common ground on which elements of drug pricing to address.
First hearing in Sen. Alexander's committee was dominated by Democrat complaints about Obamacare repeal; now that there's an actual bill to criticize, the next one might have been even worse, but regardless of the reason, the postponement means innovator prices get to stay out of the spotlight once again.